Cancer Family
Respiratory System Neoplasm
CI-CAN-00000049Explore in graph →
Non-malignant2,727 active trials51 approved drugs619 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000049Explore in graph →
Clinical trials
11,614 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02437136 | Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in Non-small Cell Lung Cancer (NSCLC) With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer (CRC) | completed | Phase 1 / Phase 2 | 191 | Syndax PharmaceuticalsINDUSTRY | 1 | Mar 20, 2025 | clinicaltrials |
| NCT04256707 | Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment(SPRINT) | completed | Phase 1 / Phase 2 | 126 | Karyopharm Therapeutics Inc |
| 1 |
| Mar 19, 2025 |
| clinicaltrials |
| NCT02489903 | RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT) | completed | Phase 2 | 139 | EpicentRx, Inc.INDUSTRY | 1 | Mar 17, 2025 | clinicaltrials |
| NCT03676192 | To Compare Efficacy and Safety of CT-P16 and European Union-Approved Avastin as First-Line Treatment for Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer | completed | Phase 3 | 689 | CelltrionINDUSTRY | 1 | Mar 17, 2025 | clinicaltrials |
| NCT05058560 | Tislelizumab in Addition to BACE in Patients with NSCLC | completed | Phase 2 | 30 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Mar 13, 2025 | clinicaltrials |
| NCT04172506 | A Study to Evaluate the Efficacy and Safety of Anti-PD-1 Antibody AK105 in Patients With Selected Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 65 | AkesoINDUSTRY | 1 | Mar 12, 2025 | clinicaltrials |
| NCT04934865 | Real Life Study Evaluating the Clinical and Organisational Impact of Moovcare® Lung Connected Medical Device in Lung Cancer Patients : REAL-MOOV-LUNG(REAL-MOOV-LUNG) | completed | N/A | 240 | Institut CurieOTHER | 1 | Mar 12, 2025 | clinicaltrials |
| NCT05505825 | A Study of AK104 in Combination With Chiauranib in Patients With Extensive Stage Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 36 | AkesoINDUSTRY | 2 | Mar 12, 2025 | clinicaltrials |
| NCT06536140 | The Lived Experiences of Persons With Early Stage Non-small Cell Lung Cancer and Their Significant Other(s) Following Surgery: a Rapid Ethnographic Approach(LEILA) | completed | — | 16 | Hasselt UniversityOTHER | 1 | Mar 12, 2025 | clinicaltrials |
| NCT04960735 | Implementation, Effectiveness and Impact of a Value Based Intervention for Patients with Breast or Lung Cancer(VOICE) | completed | N/A | 1,007 | Biosistemak Institute for Health Systems ResearchOTHER | 5 | Mar 10, 2025 | clinicaltrials |
| NCT05619744 | A Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of RO7616789 in Advanced Small Cell Lung Cancer and Other Neuroendocrine Carcinomas | completed | Phase 1 | 41 | Hoffmann-La RocheINDUSTRY | 5 | Mar 10, 2025 | clinicaltrials |
| NCT05697198 | PRospective REgistry of Advanced Stage CancER (PREFER) Patients to Assess Prevalence of Actionable Biomarkers and Driver Mutations to Address Disparities in Precision Medicine(PREFER) | completed | — | 1,429 | Labcorp Corporation of America Holdings, IncINDUSTRY | 1 | Mar 6, 2025 | clinicaltrials |
| NCT00446225 | Phase III Study (Tarceva®) vs Chemotherapy to Treat Advanced Non-Small Cell Lung Cancer in Patients With Mutations in the TK Domain of EGFR(EURTAC) | completed | Phase 3 | 174 | Spanish Lung Cancer GroupOTHER | 3 | Mar 5, 2025 | clinicaltrials |
| NCT03868579 | Rapid On Site Evaluation of Pleural Touch Preparations in Diagnosing Malignant Pleural Effusion in Patients Undergoing Pleuroscopy | completed | N/A | 97 | M.D. Anderson Cancer CenterOTHER | 2 | Mar 5, 2025 | clinicaltrials |
| NCT06495008 | Taste and Smell Dysfunction in Patients More Than Two Years After Start of Immune Checkpoint Inhibitor Therapy(TasteSPICIER) | completed | — | 101 | University Medical Center GroningenOTHER | 1 | Mar 5, 2025 | clinicaltrials |
| NCT03812549 | Safety and Tolerability Evaluation of Sintilimab in Combination With Radiation in Stage IV NSCLC Patients | completed | Phase 1 | 29 | Sichuan UniversityOTHER | 1 | Mar 4, 2025 | clinicaltrials |
| NCT06855966 | Feasibility of ETCO₂ Changes During Passive Leg Raise for Fluid Management in Lung Surgery | completed | N/A | 53 | Istanbul University - CerrahpasaOTHER | 1 | Mar 4, 2025 | clinicaltrials |
| NCT02535338 | Erlotinib Hydrochloride and Onalespib Lactate in Treating Patients With Recurrent or Metastatic EGFR-Mutant Non-small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 11 | National Cancer Institute (NCI)NIH | 1 | Mar 3, 2025 | clinicaltrials |
| NCT04880863 | NAP in Combination With Docetaxel Following Obinutuzumab Pretreatment in Subjects With Checkpoint Inhibitor Pretreated Advanced or Metastatic NSCLC(NT-NAP-102-1) | completed | Phase 2 | 38 | NeoTX Therapeutics Ltd.INDUSTRY | 1 | Mar 3, 2025 | clinicaltrials |
| NCT04005716 | Study of Platinum Plus Etoposide With or Without Tislelizumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer | completed | Phase 3 | 457 | BeiGeneINDUSTRY | 1 | Feb 28, 2025 | clinicaltrials |
| NCT04182815 | Transbronchial Biopsy Assisted by Robot Guidance in the Evaluation of Tumors of the Lung(TARGET) | completed | — | 691 | Auris Health, Inc.INDUSTRY | 3 | Feb 28, 2025 | clinicaltrials |
| NCT04206787 | The Study Observes Afatinib as First-line Treatment in Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive Advanced Non-small Cell Lung Cancer | completed | — | 72 | Boehringer IngelheimINDUSTRY | 1 | Feb 28, 2025 | clinicaltrials |
| NCT03058289 | A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6(IT-01) | completed | Phase 1 / Phase 2 | 111 | Intensity Therapeutics, Inc.INDUSTRY | 2 | Feb 27, 2025 | clinicaltrials |
| NCT03089125 | Brief Behavioral Intervention for Dyspnea in Patients With Advanced Lung Cancer | completed | N/A | 247 | Massachusetts General HospitalOTHER | 1 | Feb 27, 2025 | clinicaltrials |
| NCT03543683 | Combination of Osimertinib and Aspirin to Treat 1st Generation EGFR-TKI Resistance in NSCLC | completed | Phase 2 | 115 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityOTHER | 1 | Feb 27, 2025 | clinicaltrials |
| NCT06168825 | Mind Over Matter for Black and African American Women: A Single Arm Trial Examining Feasibility and Acceptability of a Supportive Intervention(MOM) | completed | — | 40 | Inova Health Care ServicesOTHER | 1 | Feb 27, 2025 | clinicaltrials |
| NCT02424617 | A Study of BGB324 (Bemcentinib) in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 40 | BerGenBio ASAINDUSTRY | 1 | Feb 26, 2025 | clinicaltrials |
| NCT04974632 | Mobile 3D C-arm CT for Lung Tumor Localization Efficacy Analysis: a Prospective Clinical Trial | completed | N/A | 41 | Chang Gung Memorial HospitalOTHER | 1 | Feb 26, 2025 | clinicaltrials |
| NCT05131815 | The BurnAlong Pilot Study for Adolescent and Young Adult Cancer Survivors | completed | N/A | 8 | Cedars-Sinai Medical CenterOTHER | 1 | Feb 26, 2025 | clinicaltrials |
| NCT04997382 | Chemotherapy Combined with ICIs in First-line Alectinib Failed Patients with ALK-rearranged NSCLC(CLASSIC5) | completed | Phase 2 | 112 | Hunan Province Tumor HospitalOTHER | 1 | Feb 25, 2025 | clinicaltrials |
| NCT06474611 | Evaluation of a Patient 'nudge' on Engagement in Lung Cancer Screening | completed | N/A | 894 | Kaiser PermanenteOTHER | 1 | Feb 25, 2025 | clinicaltrials |
| NCT06438367 | TGRX-326 Pharmacokinetic Mass Balance | completed | Phase 1 | 6 | Shenzhen TargetRx Co., Ltd.INDUSTRY | 1 | Feb 21, 2025 | clinicaltrials |
| NCT05000684 | Study of JS004 Combined With Toripalimab for Advanced Lung Cancer | completed | Phase 1 / Phase 2 | 67 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Feb 20, 2025 | clinicaltrials |
| NCT05555199 | Injection of 99mTc-nanocolloid and ICG to Identify, Retrieve and Qualify TDLN in Early-stage NSCLC(INITIATE) | completed | N/A | 72 | Radboud University Medical CenterOTHER | 1 | Feb 20, 2025 | clinicaltrials |
| NCT02597946 | Afatinib in NSCLC With HER2 Mutation | completed | Phase 2 | 18 | Boehringer IngelheimINDUSTRY | 2 | Feb 19, 2025 | clinicaltrials |
| NCT03088813 | Study of Irinotecan Liposome Injection (ONIVYDE®) in Patients With Small Cell Lung Cancer(RESILIENT) | completed | Phase 3 | 491 | IpsenINDUSTRY | 18 | Feb 19, 2025 | clinicaltrials |
| NCT04357873 | Efficacy of Immunotherapy Plus a Drug in Patients With Progressive Advanced Mucosal Cancer of Different Locations(PEVOsq) | completed | Phase 2 | 112 | UNICANCEROTHER | 1 | Feb 19, 2025 | clinicaltrials |
| NCT04023812 | Stage III NSCLC RWE in Chinese Patients | completed | — | 500 | AstraZenecaINDUSTRY | 1 | Feb 18, 2025 | clinicaltrials |
| NCT05227261 | Early Detection of Five Common Cancers Using the ctDNA Analysing Test(K-DETEK) | completed | — | 9,057 | Gene SolutionsINDUSTRY | 1 | Feb 18, 2025 | clinicaltrials |
| NCT03190174 | Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers | completed | Phase 1 / Phase 2 | 34 | Sarcoma Oncology Research Center, LLCOTHER | 1 | Feb 17, 2025 | clinicaltrials |
| NCT00708448 | Early Prediction of Therapeutic Response to Targeted Therapy in Stage IIIB/IV or Recurrent Lung Cancer Patients | completed | Phase 1 | 26 | University of UtahOTHER | 1 | Feb 13, 2025 | clinicaltrials |
| NCT00984321 | A Pilot Study of Geriatric Specific Interventions for Quality of Life in Elderly Patients With Cancer | completed | N/A | 107 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 13, 2025 | clinicaltrials |
| NCT03669523 | Denosumab and Nivolumab Combination As 2d-line Therapy in Stage IV NSC Lung Cancer with Bone Metastases (DENIVOS)(DENIVOS) | completed | Phase 2 | 82 | Centre Hospitalier Annecy GenevoisOTHER | 1 | Feb 13, 2025 | clinicaltrials |
| NCT03992664 | Education Intervention in Patients with Rash Due to Epidermal Growth Factor Receptor (EGFR) Treatment. | completed | N/A | 40 | Cyprus University of TechnologyOTHER | 1 | Feb 13, 2025 | clinicaltrials |
| NCT01346540 | A Phase I/II Study of Continuous Oral Treatment With BIBF 1120 Added to Standard Gemcitabine/Cisplatin Therapy in First Line NSCLC Patients With Squamous Cell Histology. | completed | Phase 1 | 16 | Boehringer IngelheimINDUSTRY | 4 | Feb 12, 2025 | clinicaltrials |
| NCT05795959 | Ensuring Precision-Medicine Delivery for Veterans With Lung Cancer | completed | N/A | 46 | Stanford UniversityOTHER | 1 | Feb 12, 2025 | clinicaltrials |
| NCT02300298 | Nintedanib Plus Docetaxel in Japanese Patients With Adenocarcinoma Subtype Non-small Cell Lung Cancer After Failure of First Line Chemotherapy | completed | Phase 1 | 10 | Boehringer IngelheimINDUSTRY | 1 | Feb 11, 2025 | clinicaltrials |
| NCT03414814 | Osimertinib for NSCLC With EGFR Exon 20 Insertion Mutation | completed | Phase 2 | 15 | Seoul National University HospitalOTHER | 1 | Feb 11, 2025 | clinicaltrials |
| NCT04230408 | Intensified Chemo-immuno-radiotherapy With Durvalumab for Stage III Non-Small Cell Lung Cancers(PACIFIC BRAZIL) | completed | Phase 2 | 48 | Latin American Cooperative Oncology GroupOTHER | 1 | Feb 11, 2025 | clinicaltrials |
| NCT02733159 | Pembrolizumab in Patients With Non-Small Cell Lung Cancer and a Performance Status 2(PePS2) | completed | Phase 2 | 62 | University of BirminghamOTHER | 1 | Feb 10, 2025 | clinicaltrials |
Data updated 24 days agoSource updated Mar 20, 2025source: clinicaltrials